Vigil Neuroscience Investor Relations Material
Latest events
Investor Update
Vigil Neuroscience
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vigil Neuroscience Inc
Access all reports
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focusing on developing treatments for both rare and common neurodegenerative diseases. The company aims to enhance the function of microglia, which are critical immune cells in the brain, to combat these diseases. Vigil Neuroscience's approach involves using precision medicine to develop targeted drug candidates, particularly focusing on the triggering receptor expressed on myeloid cells 2 (TREM2). Their drug development programs are centered on activating TREM2 to address conditions associated with microglial dysfunction, such as Alzheimer's disease. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
VIGL
Country
🇺🇸 United States